These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 23960242)

  • 1. Development of anthropomorphic hand phantoms for personal dosimetry in 90Y-Zevalin preparation and patient delivering.
    Ciolini R; d'Errico F; Traino AC; Paternostro E; Laganà A; Romei C; Pazzagli F; Del Gratta A
    Radiat Prot Dosimetry; 2014 Jan; 158(2):216-20. PubMed ID: 23960242
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radioimmunotherapy of non-Hodgkin's lymphoma with 90Y-DOTA humanized anti-CD22 IgG (90Y-Epratuzumab): do tumor targeting and dosimetry predict therapeutic response?
    Sharkey RM; Brenner A; Burton J; Hajjar G; Toder SP; Alavi A; Matthies A; Tsai DE; Schuster SJ; Stadtmauer EA; Czuczman MS; Lamonica D; Kraeber-Bodere F; Mahe B; Chatal JF; Rogatko A; Mardirrosian G; Goldenberg DM
    J Nucl Med; 2003 Dec; 44(12):2000-18. PubMed ID: 14660727
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radiation dosimetry results from a Phase II trial of ibritumomab tiuxetan (Zevalin) radioimmunotherapy for patients with non-Hodgkin's lymphoma and mild thrombocytopenia.
    Wiseman GA; Leigh BR; Erwin WD; Sparks RB; Podoloff DA; Schilder RJ; Bartlett NL; Spies SM; Grillo-López AJ; Witzig TE; White CA
    Cancer Biother Radiopharm; 2003 Apr; 18(2):165-78. PubMed ID: 12804042
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials.
    Wiseman GA; Kornmehl E; Leigh B; Erwin WD; Podoloff DA; Spies S; Sparks RB; Stabin MG; Witzig T; White CA
    J Nucl Med; 2003 Mar; 44(3):465-74. PubMed ID: 12621016
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Additional radiation absorbed dose estimates for Zevalin radioimmunotherapy.
    Wiseman GA; Leigh BR; Dunn WL; Stabin MG; White CA
    Cancer Biother Radiopharm; 2003 Apr; 18(2):253-8. PubMed ID: 12804052
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Three-dimensional patient-specific dosimetry in radioimmunotherapy with 90Y-ibritumomab-tiuxetan.
    D'Arienzo M; Cicone F; Chiacchiararelli L; Coniglio A; Delaloye AB; Scopinaro F
    Cancer Biother Radiopharm; 2012 Mar; 27(2):124-33. PubMed ID: 22283680
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bias reduction in correlation of radiation-absorbed dose with response.
    Koral KF; Zasadny K; Wahl RL
    J Nucl Med; 2004 Jul; 45(7):1271; author reply 1271-2. PubMed ID: 15235076
    [No Abstract]   [Full Text] [Related]  

  • 8. Therapeutic potential of 90Y- and 131I-labeled anti-CD20 monoclonal antibody in treating non-Hodgkin's lymphoma with pulmonary involvement: a Monte Carlo-based dosimetric analysis.
    Song H; Du Y; Sgouros G; Prideaux A; Frey E; Wahl RL
    J Nucl Med; 2007 Jan; 48(1):150-7. PubMed ID: 17204712
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison between 2D and 3D dosimetry protocols in 90Y-ibritumomab tiuxetan radioimmunotherapy of patients with non-Hodgkin's lymphoma.
    Assié K; Dieudonné A; Gardin I; Buvat I; Tilly H; Vera P
    Cancer Biother Radiopharm; 2008 Feb; 23(1):53-64. PubMed ID: 18298329
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 90Y-DOTA-hLL2: an agent for radioimmunotherapy of non-Hodgkin's lymphoma.
    Griffiths GL; Govindan SV; Sharkey RM; Fisher DR; Goldenberg DM
    J Nucl Med; 2003 Jan; 44(1):77-84. PubMed ID: 12515879
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radiation absorbed dose estimation for 90Y-DOTA-biotin with pretargeted NR-LU-10/streptavidin.
    Breitz HB; Fisher DR; Goris ML; Knox S; Ratliff B; Murtha AD; Weiden PL
    Cancer Biother Radiopharm; 1999 Oct; 14(5):381-95. PubMed ID: 10850323
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radiation dosimetry for 90Y-2IT-BAD-Lym-1 extrapolated from pharmacokinetics using 111In-2IT-BAD-Lym-1 in patients with non-Hodgkin's lymphoma.
    DeNardo GL; O'Donnell RT; Shen S; Kroger LA; Yuan A; Meares CF; Kukis DL; DeNardo SJ
    J Nucl Med; 2000 May; 41(5):952-8. PubMed ID: 10809213
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of organ absorbed doses and estimation of effective doses from pediatric anthropomorphic phantom measurements for multi-detector row CT with and without automatic exposure control.
    Brisse HJ; Robilliard M; Savignoni A; Pierrat N; Gaboriaud G; De Rycke Y; Neuenschwander S; Aubert B; Rosenwald JC
    Health Phys; 2009 Oct; 97(4):303-14. PubMed ID: 19741359
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A performance evaluation of 90Y dose-calibrator measurements in nuclear pharmacies and clinics in the United States.
    Schultz MK; Cessna JT; Anderson TL; Ponto JA; Petry N; Kowalsky RJ; Palmer MR; Beinlich UF; Baker W; Hinkle GH; Hung JC; Quinton T; Rice PA; Divgi C; Norenberg JP
    Appl Radiat Isot; 2008 Feb; 66(2):252-60. PubMed ID: 17933545
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Underestimation of absorbed dose to kidney.
    Postema EJ; Buijs WC; Boerman OC; Oyen WJ
    J Nucl Med; 2003 Oct; 44(10):1707-8. PubMed ID: 14530491
    [No Abstract]   [Full Text] [Related]  

  • 16. Dose rates in nuclear medicine and the effectiveness of lead aprons: updating the department's knowledge on old and new procedures.
    Young AM
    Nucl Med Commun; 2013 Mar; 34(3):254-64. PubMed ID: 23353888
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radiation safety considerations with therapeutic 90Y Zevalin.
    Zhu X
    Health Phys; 2003 Aug; 85(2 Suppl):S31-5. PubMed ID: 12865747
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimizing radioimmunotherapy by matching dose distribution with tumor structure using 3D reconstructions of serial images.
    Flynn AA; Pedley RB; Green AJ; Boxer GM; Boden R; Begent RH
    Cancer Biother Radiopharm; 2001 Oct; 16(5):391-400. PubMed ID: 11776756
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnostic imaging prior to 90Y-ibritumomab tiuxetan (Zevalin) treatment in follicular non-Hodgkin's lymphoma.
    Otte A
    Hell J Nucl Med; 2008; 11(1):12-5. PubMed ID: 18392220
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase I study of 90yttrium-ibritumomab-tiuxetan in children and adolescents with relapsed/refractory CD20-positive non-Hodgkin's lymphoma: a Children's Oncology Group study.
    Cooney-Qualter E; Krailo M; Angiolillo A; Fawwaz RA; Wiseman G; Harrison L; Kohl V; Adamson PC; Ayello J; vande Ven C; Perkins SL; Cairo MS;
    Clin Cancer Res; 2007 Sep; 13(18 Pt 2):5652s-5660s. PubMed ID: 17875803
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.